JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Cellectis SA (CLLS – Research Report) today and set a price target of $6.00. The company’s shares closed last Friday at $1.99.
According to TipRanks, Tuerkcan is an analyst with an average return of -3.5% and a 27.78% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Cellectis SA, Crispr Therapeutics AG, and Vor Biopharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cellectis SA with a $13.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $5.04 and a one-year low of $1.83. Currently, Cellectis SA has an average volume of 158.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
- Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Cellectis reports Q4 EPS (59c), consensus (71c)
- Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
- Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
- Monthly information on share capital and company voting rights
